OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune. Infos Cours Ma liste. Tedopi (OSE-2101) - Immuno-Oncology News OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. cours. NANTES, France, December 13, 2021--OSE Immuno is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis Produced with the support of BIO, it is regarded as a "must attend" event for the biotech industry. NANTES, France, May 23, 2022--Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring neoepitope combination Tedopi® in various cancer indications at the American Society of Clinical Oncology (ASCO . OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. OSE Immunotherapeutics To Present at 'Immuno-Oncology Summit Europe ... OSE Immunotherapeutics : Présentation synthétique des résolutions OSE Immunotherapeutics: ClinicalTrials.gov Identifier: NCT04882007 Other Study ID Numbers: OSE-127-C201 2020-001398-59 ( EudraCT Number ) First Posted: May 11, 2021 Key Record Dates: Last Update Posted: June 28, 2021 Last Verified: June 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: